NXY-059: Brain or Vessel Protection

Cosmic implications of NXY-059.

The SAINT studies on NXY-0591,2 have reinvigorated debate over the momentous issues of neuroprotection and the development of novel stroke therapeutics. Some may argue there is little new ground that NXY-059 has unearthed and, in fact, the clinical trials merely confirm that as a strategy, neuroprotection has not been shown to be effective. Editorials in high-profile journals have sent out the ...

Brain or Vessel Protection

NXY-059 is a nitrone compound with free radical trapping properties that appears to be neuroprotective in some animal models of stroke.1,2 The publication this month of SAINT-I trial in the New England Journal of Medicine3 demonstrates a small but statistically significant improvement of the primary outcome by NXY-059 treatment. The authors observed reduced disability at 90 days as assessed by ...

NXY-059 for acute ischemic stroke.

BACKGROUND NXY-059 is a free-radical-trapping agent that is neuroprotective in animal models of stroke. We tested whether it would reduce disability in humans after acute ischemic stroke. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 1722 patients with acute ischemic stroke who were randomly assigned to receive a 72-hour infusion of placebo or intravenous...

NXY-059: a hopeful sign in the treatment of stroke.

The SAINT I trial published in the February 9, 2006 issue of the New England Journal of Medicine represents the first “positive” neuroprotective trial in stroke.1 This breaks a long string of “neuroprotective” failures and indicates some hope for stroke treatment.2 Is NXY-059 a better drug than previous failed agents or was the trial just better designed? Probably both. NXY-059 is the first age...

NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized?